GlassScriptPhysician profile
Nagaraja D Sharma
NPI 1275528804
$12,781.07
in general payments reported to CMS, 2019-2025
28 companies · $8,057 in 2025
The $8,057 reported for 2025 was more than what 94% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $602 · 2020: $982 · 2021: $918 · 2022: $851 · 2023: $477 · 2024: $893 · 2025: $8,057.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $6,667 · Food and Beverage: $2,372 · Travel and Lodging: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $6,666.67 |
| Food and Beverage | $2,372.31 |
| Travel and Lodging | $387.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $6,666.67 | 2025 | Auryon Laser System 100-120 Vac |
| Boston Scientific Corporation | $729.43 | 2019-2025 | Versacross Connect Laac Access Solution, General - Therapies, Farapulse |
| Boehringer Ingelheim Pharmaceuticals, INC. | $648.19 | 2019-2025 | Jardiance |
| Edwards Lifesciences Corporation | $599.27 | 2020-2025 | Sapien 3 Ultra Resilia |
| Medtronic, INC. | $523.05 | 2022-2025 | Corevalve Evolut R, Micra |
| Abbott Laboratories | $426.97 | 2019-2025 | Navitor, Cardiomems, Mitraclip |
| Merck Sharp & Dohme LLC | $381.20 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $380.53 | 2019-2024 | Xarelto |
| Amarin Pharma, INC. | $376.20 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $262.79 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $251.23 | 2019-2024 | Farxiga |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $176.97 | 2021-2025 | Lifevest |
| Astellas Pharma US INC | $164.09 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $139.17 | 2019-2024 | Camzyos, Eliquis |
| Amgen INC. | $138.96 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $116.79 | 2019-2024 | |
| Novo Nordisk INC | $115.14 | 2021-2025 | Wegovy |
| Irhythm Technologies, INC. | $85.40 | 2023-2024 | Zio Xt Patch, Zio Monitor |
| Scpharmaceuticals INC. | $81.74 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $77.59 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $70.31 | 2024 | |
| Philips North America LLC | $69.85 | 2025 | Ecc Solutions, Mcot |
| Esperion Therapeutics, INC. | $61.35 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $60.35 | 2023-2025 | Assure Wcd |
| Sanofi-Aventis U.S. LLC | $60.34 | 2023 | |
| Abiomed | $60.00 | 2019 | |
| Cardiovascular Systems INC. | $32.29 | 2019-2020 | |
| Medicomp INC | $25.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nagaraja Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.